ChemicalBook > Product Catalog >Pharmaceutical intermediates >Bulk Drug Intermediates >2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone

2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone

2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone Suppliers list
Company Name: HSDK(Nanjing)Pharma Tech Co.,Ltd.  Gold
Tel: 15189849794
Email: xiaojin.wu@hsdk-pharmatech.cn
Company Name: EVERSHINE CHEMICAL CO., LIMITED  Gold
Tel: 17185714011
Email: 3506894070@qq.com
Company Name: Hangzhou Bright Pharma Biotechnology Co., Ltd.  Gold
Tel: 0571-85775770 13575490453
Email: info@brightpharmabio.com
Company Name: Anqing CHICO Pharmaceutical Co., Ltd.  Gold
Tel: 18061456370
Email: sales@chicopharm.com
Company Name: Jiangsu Haici Biopharmaceutical Co., Ltd.  Gold
Tel: 15722465851 15722465851
Email: 2545001360@qq.com
2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone Basic information
Description Reference
Product Name:2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone
Synonyms:(3R,4S,5R,6R)-3,4,5-tris(triMethylsilyloxy)-6-((triMethylsilyloxy)Methyl)tetrahydro-2H-pyran-2-one;2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone;D-2,3,4,6-Tetrakis-O-(trimethylsilyl)-gluconic acid delta-lactone;2,3,4,6-Tetrakis-O-triMethylsilyl-D-gluconolactoe;D-Gluconic acid, 2,3,4,6-tetrakis-O-(triMethylsilyl)-, d-lactone;2,3,4,6-tetrakis-O-trimethylsilyl-D-glucono1,5 lactone;(3R,5R,6R)-3,4,5-Tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one;(3R,4S,5R,6R)-3,4,5-tris(trimethylsilyloxy)-6-(trimethylsilyloxymethyl)oxan-2-one
CAS:32384-65-9
MF:C18H42O6Si4
MW:466.87
EINECS:608-732-8
Product Categories:32384-65-9
Mol File:32384-65-9.mol
2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone Structure
2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone Chemical Properties
Boiling point 417℃
density 0.97
Fp 171℃
storage temp. under inert gas (nitrogen or Argon) at 2-8°C
solubility Chloroform (Sparingly), Ethyl Acetate (Slightly), Methanol (Slightly)
form Oil
color Colourless to Pale Yellow
Optical Rotation46.568°(C=0.01g/ml CHCL3)
Stability:Moisture Sensitive
InChIInChI=1/C18H42O6Si4/c1-25(2,3)20-13-14-15(22-26(4,5)6)16(23-27(7,8)9)17(18(19)21-14)24-28(10,11)12/h14-17H,13H2,1-12H3/t14-,15-,16+,17-/s3
InChIKeyVNGTZLYNGGLPIZ-NELUYGJANA-N
SMILESO([C@@H]1[C@H](C(=O)O[C@H](CO[Si](C)(C)C)[C@H]1O[Si](C)(C)C)O[Si](C)(C)C)[Si](C)(C)C |&1:1,2,6,13,r|
Safety Information
HS Code 2931900090
MSDS Information
2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone Usage And Synthesis
DescriptionIt is usually used as the intermediate and raw material in the chemistry synthesis and pharmaceutical industry. Especially, this chemical has been widely used in the design and synthesis of sodium-glucose transporter inhibitors.1 For example, this substance can be employed as raw material in the preparation of (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-ethoxylphenyl)methyl]phenyl]-D-glucitol, which is commonly known as Dapagliflozin that act as the sodium dependent glucose transporters for treating type 2 diabetes.2 Moreover, it can also function as the intermediate for synthesizing empagliflozin, which is a novel and selective sodium glucose co-transporter-2 inhibitor.3 In addition, canagliflozin, another sodium glucose co-transporter-2 inhibitor, can be obtained by utilizing this substance as the intermediate.4
Reference
  1. Guo, C.; Hu, M.; DeOrazio, R. J.; Usyatinsky, A.; Fitzpatrick, K.; Zhang, Z. J.; Maeng, J. H.; Kitchen, D. B.; Tom, S.; Luche, M.; Khmelnitsky, Y.; Mhyre, A. J.; Guzzo, P. R.; Liu, S., The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties. Bioorg. Med. Chem. 2014, 22, 3414-3422.
  2. S Thirumalai Rajan; Eswaraiah, S., Process for the preparation of (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxylphenyl)methyl]phenyl]-D-glucitol and its solvate thereof. US Patent 2015, WO 2015/132803 A2.
  3. Hrapchak, M.; Latli, B.; Wang, X. J.; Lee, H.; Campbell, S.; Song, J. J.; Senanayake, C. H., Synthesis of empagliflozin, a novel and selective sodium-glucose co-transporter-2 inhibitor, labeled with carbon-14 and carbon-13. J. Label. Compd. Radiopharm. 2014, 57, 687-694.
  4. Nomura, S.; Sakamaki, S.; Hongu, M.; Kawanishi, E.; Koga, Y.; Sakamoto, T.; Yamamoto, Y.; Ueta, K.; Kimata, H.; Nakayama, K.; Tsuda-Tsukimoto, M., Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. J. Med. Chem. 2010, 53, 6355-6360.
Chemical PropertiesPale yellow oil
Uses2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone is an antidiabetic agent and an intermediate of Dapagliflozin (D185370). 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone acts as a reagent in the synthesis of trans-cyclohexane-bearing C-glucose as sodium glucose co-transporter 2 inhibitors.
Synthesis At present, the publicly reported synthesis process of 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone is mainly prepared by the synthesis of D-gluconolactone and trimethylsilyl chloride in the presence of an acid-binding agent or the preparation of D-gluconolactone and hexamethyldisilazane in dichloromethane reflux. The former has problems such as high pH requirements, low atom economy, and severe pollution. In contrast, the latter has such problems as the large amount of hexamethyldisilazane used, the strong volatility of dichloroethane, and severe pollution. Therefore, Li et al. developed a method for preparing 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone, comprising the following operations: reacting D-gluconolactone with hexamethyldisilazane in an ionic liquid at standard pressure, and removing the ionic liquid by reduced pressure distillation after the reaction is completed to obtain 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone; the cation in the ionic liquid is an alkyl imidazolium ion, and the anion in the ionic liquid is hexafluorophosphate, tetrafluoroborate, tetrachloroaluminate or chloride ion.
References[1] Patent: US2011/237789, 2011, A1. Location in patent: Page/Page column 11-12
[2] Patent: US2011/237526, 2011, A1. Location in patent: Page/Page column 7; 8
[3] Patent: US2013/267694, 2013, A1. Location in patent: Page/Page column 0297-0301
[4] Patent: WO2015/43473, 2015, A1. Location in patent: Paragraph 00113
[5] Patent: US2015/191502, 2015, A1. Location in patent: Paragraph 0084
2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone Preparation Products And Raw materials
Raw materialsHexamethyldisilazane-->Chlorotrimethylsilane-->D-Glucono-1,5-lactone-->D-galactono-1,5-lactone-->4-Methylmorpholine-->Tetrahydrofuran-->4-Dimethylaminopyridine
Tag:2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone(32384-65-9) Related Product Information
2-(5-BroMo-2-Methylbenzyl)-5-(4-fluorophenyl)thiophene 5-bromo-2-chloro-4’-ethoxydiphenylmethane (R)-3-(4-(5-broMo-2-chlorobenzyl)phenoxy)tetrahydrofuran 4-(5-broMo-2-chlorobenzyl)phenol Acarbose 5-Bromo-2-methylbenzoic acid D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]Methyl]-4-Methylphenyl]-, tetraacetate, (1S)- (9CI) (5-broMo-2-Methylphenyl)(5-(4-fluorophenyl)thiophen-2-yl)Methanone 2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene 5-Bromo-2-methylbenzoyl chloride 5-Iodo-2-methylbenzoic acid Canagliflozin heMihydrate LIPOPHILIC SEPHADEX 2-(4-Fluorophenyl)-thiophene BCP19353 Canagliflozin 5-Bromo-2-chlorobenzoic acid (5-broMo-2-chlorophenyl)(2-ethoxyphenyl)Methanone